General Session 3
Session Details
Moderator
Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center, New York, NY
Moderator
Shou-Ching Tang, LSU School of Medicine, New Orleans, New Orleans, LA
Presentation numberGS3-1
Final overall survival of imlunestrant versus standard of care in ESR1-mutated advanced breast cancer: updated efficacy from the phase 3 EMBER-3 trial
Komal L Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberGS3-2
Camizestrant + palbociclib (palbo) vs anastrozole (ana) + palbo as upfront first-line (1L) therapy in patients (pts) with ER+/HER2- advanced breast cancer (ABC): results from the randomized phase 3 SERENA-4 trial
Fabrice André, Institut Gustave Roussy, Villejuif, France
Presentation numberGS3-3
Discussant for 3305 and 3459
Aditya Bardia, University of California Los Angeles, Los Angeles, CA
Presentation numberGS3-4
Characterization of clinical outcomes in monarchE by histologic, molecular, and genomic subtypes: Updated baseline tumor analysis from patients with HR+, HER2−, node-positive, high-risk early breast cancer
Nick Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
Presentation numberGS3-5
Longitudinal analysis of imaging biomarkers and ctDNA to predict neoadjuvant therapy response: a retrospective study from I-SPY 2
Wen Li, University of California, San Francisco, San Francisco, CA
Presentation numberGS3-6
Translational discovery and validation of genomic alterations associated with AKT inhibitor (AKTi) resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)
Maxwell R Lloyd, Massachusetts General Hospital, Boston, MA
Presentation numberGS3-7
Vaccination to target PARP inhibitor resistance caused by BRCA1/2 reversion mutations
Stephen J. Pettitt, Institute of Cancer Research, London, United Kingdom
Presentation numberGS3-8
Efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy versus standard of care (SoC) therapy in stage I-II HER2+ early breast cancer (eBC): First results from WSG ADAPT-HER2-IV
Nadia Harbeck, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
Presentation numberGS3-9
Trastuzumab rezetecan with or without pertuzumab in untreated HER2-positive recurrent or metastatic breast cancer: a multicenter, randomized phase 3 study (HORIZON-Breast07)
Yongmei Yin, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Presentation numberGS3-10
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients (pts) with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062)
Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA